The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Prolixin     2-[4-[3-[2-(trifluoromethyl) phenothiazin...

Synonyms: Permitil, Siqualon, Anatensol, Dapotum, Pacinol, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of FLUPHENAZINE


Psychiatry related information on FLUPHENAZINE


High impact information on FLUPHENAZINE


Chemical compound and disease context of FLUPHENAZINE


Biological context of FLUPHENAZINE


Anatomical context of FLUPHENAZINE


Associations of FLUPHENAZINE with other chemical compounds

  • Two hundred and ninety newly hospitalized patients at four hospitals were randomly assigned to groups receiving either long-acting injectable fluphenazine decanoate or short-acting oral fluphenazine hydrochloride [27].
  • Twenty-eight patients who had recently recovered from an acute-onset, first-episode schizophrenic illness were randomly given fluphenazine hydrochloride or decanoate or placebo for a one-year period in a double-blind study [28].
  • The CaM antagonists, fluphenazine, compound 48/80, and calcineurin at concentrations abolishing CaM stimulation of bovine brain PDE had little effect on the activity of reconstituted bovine lung phosphodiesterase [29].
  • The chaperone activity of S100A1 was antagonized by calmodulin antagonists, such as fluphenazine and prenylamine, that is, indeed an intrinsic function of the protein [30].
  • METHOD: Outpatients with schizophrenia who had histories of partial response to conventional neuroleptics and who had not responded to a prospective 6-week trial of fluphenazine participated in a 10-week, double-blind, parallel-groups comparison of clozapine and haloperidol [31].

Gene context of FLUPHENAZINE


Analytical, diagnostic and therapeutic context of FLUPHENAZINE


  1. Peripheral diabetic neuropathy treated with amitriptyline and fluphenazine. Davis, J.L., Lewis, S.B., Gerich, J.E., Kaplan, R.A., Schultz, T.A., Wallin, J.D. JAMA (1977) [Pubmed]
  2. Fluphenazine and postherpetic neuralgia. Hurtig, H.I. JAMA (1990) [Pubmed]
  3. Diabetic neuropathic cachexia. Beneficial response to combination therapy with amitriptyline and fluphenazine. Gade, G.N., Hofeldt, F.D., Treece, G.L. JAMA (1980) [Pubmed]
  4. Fluphenazine and tardive dyskinesia. Perényi, A., Arató, M. Arch. Gen. Psychiatry (1984) [Pubmed]
  5. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Rifkin, A., Quitkin, F., Klein, D.F. Arch. Gen. Psychiatry (1977) [Pubmed]
  6. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Rao, P.A., Pickar, D., Gejman, P.V., Ram, A., Gershon, E.S., Gelernter, J. Arch. Gen. Psychiatry (1994) [Pubmed]
  7. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Hogarty, G.E., McEvoy, J.P., Munetz, M., DiBarry, A.L., Bartone, P., Cather, R., Cooley, S.J., Ulrich, R.F., Carter, M., Madonia, M.J. Arch. Gen. Psychiatry (1988) [Pubmed]
  8. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Cohen, R.M., Nordahl, T.E., Semple, W.E., Andreason, P., Litman, R.E., Pickar, D. Arch. Gen. Psychiatry (1997) [Pubmed]
  9. Drug and family therapy in the aftercare of acute schizophrenics. Goldstein, M.J., Rodnick, E.H., Evans, J.R., May, P.R., Steinberg, M.R. Arch. Gen. Psychiatry (1978) [Pubmed]
  10. Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. Koreen, A.R., Lieberman, J., Alvir, J., Chakos, M., Loebel, A., Cooper, T., Kane, J. The American journal of psychiatry. (1994) [Pubmed]
  11. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. Mendel, C.M., Klein, R.F., Chappell, D.A., Dere, W.H., Gertz, B.J., Karam, J.H., Lavin, T.N., Grunfeld, C. JAMA (1986) [Pubmed]
  12. Drug interaction between ascorbic acid and fluphenazine. Dysken, M.W., Cumming, R.J., Channon, R.A., Davis, J.M. JAMA (1979) [Pubmed]
  13. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. Wolkowitz, O.M., Breier, A., Doran, A., Kelsoe, J., Lucas, P., Paul, S.M., Pickar, D. Arch. Gen. Psychiatry (1988) [Pubmed]
  14. Weight gain associated with antipsychotic drugs. Ganguli, R. The Journal of clinical psychiatry. (1999) [Pubmed]
  15. A case of neuroleptic malignant syndrome successfully treated with amantadine. McCarron, M.M., Boettger, M.L., Peck, J.J. The Journal of clinical psychiatry. (1982) [Pubmed]
  16. Serum concentration of depot neuroleptics in tardive dyskinesia. Fairbairn, A.F., Rowell, F.J., Hui, S.M., Hassanyeh, F., Robinson, A.J., Eccleston, D. The British journal of psychiatry : the journal of mental science. (1983) [Pubmed]
  17. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Costall, B., Domeney, A.M., Naylor, R.J., Tyers, M.B. Br. J. Pharmacol. (1987) [Pubmed]
  18. Calcium-regulated phosphorylation in synaptosomal cytosol: dependence on calmodulin. O'Callaghan, J.P., Dunn, L.A., Lovenberg, W. Proc. Natl. Acad. Sci. U.S.A. (1980) [Pubmed]
  19. Identification and characterization of the acidic pH binding sites for growth regulatory ligands of low density lipoprotein receptor-related protein-1. Ling, T.Y., Chen, C.L., Huang, Y.H., Liu, I.H., Huang, S.S., Huang, J.S. J. Biol. Chem. (2004) [Pubmed]
  20. 19F nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Bartels, M., Günther, U., Albert, K., Mann, K., Schuff, N., Stuckstedte, H. Biol. Psychiatry (1991) [Pubmed]
  21. Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis. Bachmeyer, C., Orlik, F., Barth, H., Aktories, K., Benz, R. J. Mol. Biol. (2003) [Pubmed]
  22. Autonomic effects of clozapine in schizophrenia: comparison with placebo and fluphenazine. Zahn, T.P., Pickar, D. Biol. Psychiatry (1993) [Pubmed]
  23. Calcium-dependent protein binding to phenothiazine columns. Moore, P.B., Dedman, J.R. J. Biol. Chem. (1982) [Pubmed]
  24. Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Cai, G., Gurdal, H., Smith, C., Wang, H.Y., Friedman, E. Mol. Pharmacol. (1999) [Pubmed]
  25. Pharmacological properties of fluphenazine-mustard, an irreversible calmodulin antagonist. Hait, W.N., Glazer, L., Kaiser, C., Cross, J., Kennedy, K.A. Mol. Pharmacol. (1987) [Pubmed]
  26. Effects of the calmodulin antagonist, fluphenazine, on phosphorylation of myosin and phosphorylase in intact smooth muscle. Silver, P.J., Stull, J.T. Mol. Pharmacol. (1983) [Pubmed]
  27. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Schooler, N.R., Levine, J., Severe, J.B., Brauzer, B., DiMascio, A., Klerman, G.L., Tuason, V.B. Arch. Gen. Psychiatry (1980) [Pubmed]
  28. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Kane, J.M., Rifkin, A., Quitkin, F., Nayak, D., Ramos-Lorenzi, J. Arch. Gen. Psychiatry (1982) [Pubmed]
  29. Purification and characterization of bovine lung calmodulin-dependent cyclic nucleotide phosphodiesterase. An enzyme containing calmodulin as a subunit. Sharma, R.K., Wang, J.H. J. Biol. Chem. (1986) [Pubmed]
  30. S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex. Okada, M., Hatakeyama, T., Itoh, H., Tokuta, N., Tokumitsu, H., Kobayashi, R. J. Biol. Chem. (2004) [Pubmed]
  31. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Breier, A., Buchanan, R.W., Kirkpatrick, B., Davis, O.R., Irish, D., Summerfelt, A., Carpenter, W.T. The American journal of psychiatry. (1994) [Pubmed]
  32. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Wang, E., Lew, K., Barecki, M., Casciano, C.N., Clement, R.P., Johnson, W.W. Chem. Res. Toxicol. (2001) [Pubmed]
  33. Atypical antipsychotics: mechanism of action. Seeman, P. Canadian journal of psychiatry. Revue canadienne de psychiatrie. (2002) [Pubmed]
  34. Parathyroid hormone activation of map kinase in rat duodenal cells is mediated by 3',5'-cyclic AMP and Ca(2+). Gentili, C., Morelli, S., Boland, R., de Boland, A.R. Biochim. Biophys. Acta (2001) [Pubmed]
  35. Fluphenazine-resistant Saccharomyces cerevisiae mutants defective in the cell division cycle. Matsumoto, K., Uno, I., Ishikawa, T. J. Bacteriol. (1986) [Pubmed]
  36. Functional analysis of the promoter of the Saccharomyces cerevisiae multidrug resistance gene YDR1, which encodes a member of the ATP binding cassette (ABC) superfamily. Miyahara, K., Hirata, D., Miyakawa, T. Biosci. Biotechnol. Biochem. (1995) [Pubmed]
  37. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients. Quitkin, F., Rifkin, A., Klein, D.F. Arch. Gen. Psychiatry (1975) [Pubmed]
  38. Low neuroleptic serum levels in patients receiving fluphenazine decanoate. Tune, L.E., Creese, I., Coyle, J.T., Pearlson, G., Snyder, S.H. The American journal of psychiatry. (1980) [Pubmed]
  39. Factors related to tardive dyskinesia. Chouinard, G., Annable, L., Ross-Chouinard, A., Nestoros, J.N. The American journal of psychiatry. (1979) [Pubmed]
  40. Fluphenazine blood levels and clinical response. Harris, P.Q., Friedman, M.J., Cohen, B.M., Cooper, T.B. Biol. Psychiatry (1982) [Pubmed]
  41. Persistence of fluphenazine in plasma after decanoate withdrawal. Gitlin, M.J., Midha, K.K., Fogelson, D., Nuechterlein, K. Journal of clinical psychopharmacology. (1988) [Pubmed]
WikiGenes - Universities